What is Lipfendra, the new cholesterol pill?
If you take a cholesterol medicine, your prescriber decides any start, stop or change, so bring this to them. Lipfendra (enlicitide) is the first pill in the PCSK9 class, approved by the FDA on July 16, 2026. In its main trial, nearly everyone was already on a statin, and adding it took LDL down about 56 percentage points more than a placebo. Nobody knows yet whether it prevents heart attacks.
What we’d do
Keep taking whatever you take now. If you’re on a statin and still well above your goal, or a statin doesn’t suit you, ask your doctor whether a second medicine makes sense, and which one. The 2026 guideline names ezetimibe, bempedoic acid and the PCSK9 injections as the medicines to add after a statin.
Why people are asking
The news called it the first cholesterol pill of its kind, and searches for it shot up after the approval. Until now PCSK9 drugs came only as injections, so a once-a-day tablet sounds like a big change.
How it works
PCSK9 is a protein that tells your liver to break down its LDL receptors, the drain that pulls LDL out of your blood. Block it and the liver keeps more receptors, so LDL falls. The idea came from people born with a broken PCSK9 gene: in a 15 year US study, Black Americans who carried one had 28% lower LDL and 88% less coronary heart disease. Where cholesterol comes from and where it goes has the drain.
What the trial found
CORALreef Lipids gave 2,909 adults, average age 63, either 20 mg of enlicitide a day or a placebo for a year. 58% had already had a heart attack, stroke or similar event, and 97% were on a statin, with an average LDL of 96 mg/dL. At 24 weeks LDL had fallen 57.1% on the pill, about 56 percentage points more than on the placebo. At a year the gap was about 48 points. Side effects, serious problems and new diabetes were about as common on the pill as on the placebo.
A second trial, in people with familial hypercholesterolemia, found a gap of about 59 points. Diarrhea (7% against 2%) and dizziness (9% against 4%) came up more often on the pill there.
What nobody knows yet
The approval rests on LDL. CORALreef Outcomes, with more than 14,500 people, is testing whether the pill cuts heart attacks and strokes, and it hasn’t reported. Lowering LDL with statins cut heart attacks and strokes in 26 trials, but that hasn’t been shown for this drug yet. The 2026 US guideline was published before the approval and doesn’t name it.
If you take a cholesterol medicine, your prescriber sets your goal and decides any start, stop or change. Keep taking it, and bring your questions to them.
8 sources
- US Food and Drug Administration, LIPFENDRA (enlicitide) tablets, prescribing information, NDA 220848, initial US approval 2026, revised July 2026accessdata.fda.gov
- Merck, LIPFENDRA (enlicitide) is the first and only once-daily oral PCSK9 inhibitor approved by the US FDA to reduce LDL-C in adults with hypercholesterolemia, press release, 16 July 2026merck.com
- Navar AM, Mikhailova E, Catapano AL and others, A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide, NEJM, 2026, 394(6):529-539doi.org
- American College of Cardiology, CORALreef Lipids: oral PCSK9 inhibitor enlicitide reduces LDL-C in high-risk patients, journal scan of the NEJM report, 9 February 2026acc.org
- Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease, NEJM, 2006pubmed.ncbi.nlm.nih.gov
- Cholesterol Treatment Trialists' Collaboration, Efficacy and safety of more intensive lowering of LDL cholesterol, Lancet, 2010pubmed.ncbi.nlm.nih.gov
- American College of Cardiology, ACC/AHA issue updated guideline for managing lipids, cholesterol, press release, 13 March 2026acc.org
- Blumenthal RS, Morris PB, Gaudino M and others, 2026 ACC/AHA guideline on the management of dyslipidemia, JACC, 2026doi.org